Revenue Breakdown
Composition ()
No data
Revenue Streams
Sanofi SA (SNY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Others, accounting for 40.7% of total sales, equivalent to $9.33B. Other significant revenue streams include Dupixent and Polio / Pertrussis / Hib. Understanding this composition is critical for investors evaluating how SNY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Sanofi SA maintains a gross margin of 68.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.17%, while the net margin is 13.85%. These profitability ratios, combined with a Return on Equity (ROE) of 8.64%, provide a clear picture of how effectively SNY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SNY competes directly with industry leaders such as BMY and REGN. With a market capitalization of $114.00B, it holds a leading position in the sector. When comparing efficiency, SNY's gross margin of 68.80% stands against BMY's 66.10% and REGN's 86.11%. Such benchmarking helps identify whether Sanofi SA is trading at a premium or discount relative to its financial performance.
